Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 20/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 20/20 | 0.60 |
| ▸ | CHRNB4 | P30926 | 20/20 | 0.60 |
| ▸ | CHRNA3 | P32297 | 20/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 20/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 20/20 | 0.60 |
| ▸ | CHRNA1 | P02708 | 19/20 | 0.60 |
| ▸ | CHRNB1 | P11230 | 19/20 | 0.60 |
| ▸ | CHRNG | P07510 | 16/20 | 0.60 |
| ▸ | CHRND | Q07001 | 16/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5448764 | 0.86 | CHRNB2 (0.61) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5456094 | 0.81 | CHRNB2 (0.62) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5460442 | 0.79 | CHRNB2 (0.60) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL5456533 | 0.79 | CHRNB2 (0.82) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5454759 | 0.79 | CHRNB2 (0.52) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL2599138 | 0.75 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL3453734 | 0.75 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL5478077 | 0.75 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL48964 | 0.75 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 | |
| Radafaxine SCHEMBL13014841 | 0.75 | CHRNB2 (1.00) | CHRNB2SLC6A2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032535-A1 | Diastereomeric dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof | Smith Kline Beecham Corporation D/b/a Glaxo Smith Kline (US) | 2007-02-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032535-A1 | Diastereomeric dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, salts, and solvates thereof | METTL3, TPMT, MTAP | CHRNB2 2457/4885SLC6A2 236/4885CHRNB4 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.